The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Regulatory News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Research Update

20 May 2015 07:00

RNS Number : 6970N
4d Pharma PLC
20 May 2015
 

4D pharma plc

(the "Company" or "4D")

Research Update on Clinical Development

4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on the development of live biotherapeutics, today provides the following research update on its Clinical Development Programmes.

The Company currently has two programmes progressing towards the clinic, Blautix, for the treatment of Irritable Bowel Syndrome ("IBS"), and Thetanix, for the treatment of Paediatric Crohn's Disease.

The Board of the Company is pleased to report that a dossier for Blautix has been submitted to Swissmedic (Swiss Agency for Therapeutic Products) and the EKNZ (Swiss ethics committee) in relation to a first in man study to be carried out in healthy volunteers and individuals exhibiting symptoms of IBS.

Thetanix also continues to progress towards a first in man study, to be carried out in Paediatric Crohn's patients. Following a development programme to further optimise the Thetanix drug product, it is now anticipated that this trial will commence in H2 2015.

Dr. Alex Stevenson, 4D's Chief Scientific Officer, commented "4D is at the forefront of the development of live biotherapeutics, a new class of drug designed to treat the underlying causes of disease rather than just the symptoms. A critical component of making live biotherapeutics a reality is the ability to rapidly translate candidates identified in the laboratory into pharmaceutical grade products that can be administered to patients. Over the last few months we have made tremendous progress in establishing a methodology that allows us to do just that. With Blautix and Thetanix approaching the clinic, we are applying this same methodology to our pipeline of novel live biotherapeutic treatments for additional indications, such as asthma and rheumatoid arthritis, in line with our goal of developing ground breaking treatments for a wide range of important diseases".

 

For further information please contact:

4D

+ 44 (0) 161 837 6205

Duncan Peyton, Chief Executive Officer

 

Zeus Capital Limited - Nomad and Broker

Dan Bate/Ross Andrews

+44 (0) 161 831 1512

Dominic Wilson

+44 (0) 20 7533 7727

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGGUQCAUPAGQB
Date   Source Headline
9th Nov 20201:00 pmRNSSITC data MRx0518 monotherapy and combination
5th Nov 202012:00 pmRNSVirtual KOL Event SITC Data
30th Oct 20204:57 pmRNSHolding(s) in Company
23rd Oct 20201:17 pmRNSHolding(s) in Company
22nd Oct 20207:00 amRNSProposed Merger & Intention to seek NASDAQ Listing
14th Oct 202010:09 amRNSHolding(s) in Company
14th Oct 20207:00 amRNSPresentations on MRx0518 at SITC 2020
12th Oct 20202:01 pmRNSHolding(s) in Company
7th Oct 20207:00 amRNSTopline Results for Blautix phase II trial
30th Sep 20207:00 amRNSInterim Results
23rd Sep 20207:00 amRNSDirectorate Change
14th Sep 20204:30 pmRNSBlock Listing Six Monthly Return
7th Sep 20205:26 pmRNSHolding(s) in Company
1st Sep 20204:58 pmRNS4D hosts virtual R&D event
26th Aug 20207:00 amRNSMRx0158 Keytruda Part A clinical benefit data
14th Aug 20204:49 pmRNSHolding(s) in Company
12th Aug 20207:00 amRNSHolding(s) in Company
28th Jul 202010:34 amRNSHolding(s) in Company
24th Jul 20204:58 pmRNSHolding(s) in Company
20th Jul 20205:09 pmRNSHolding(s) in Company
16th Jul 20206:15 pmRNSHolding(s) in Company
16th Jul 20204:43 pmRNSHolding(s) in Company
15th Jul 20204:16 pmRNSHolding(s) in Company
13th Jul 20205:57 pmRNSResult of Fundraising
13th Jul 202012:13 pmRNSPlacing and Subscription of £7.7m
6th Jul 20207:00 amRNSOncology Clinical Update
2nd Jul 20204:02 pmRNSHolding(s) in Company
2nd Jul 20207:00 amRNSCOVID-19 study open for enrolment
30th Jun 20201:05 pmRNSResult of AGM
25th Jun 20207:00 amRNSHolding(s) in Company
22nd Jun 202011:19 amRNSHolding(s) in Company
10th Jun 20205:25 pmRNSHolding(s) in Company
10th Jun 20205:17 pmRNSHolding(s) in Company
10th Jun 202011:21 amRNSHolding(s) in Company
5th Jun 20201:00 pmRNSAnnual Report and Notice of AGM
5th Jun 20207:41 amRNS4D hosts virtual R&D event
26th May 20207:00 amRNSFinal Results
21st May 20207:00 amRNSDirectorate Change
19th May 20206:20 pmRNSHolding(s) in Company
12th May 20206:06 pmRNSHolding(s) in Company
11th May 20207:00 amRNSCompletion of immuno-oncology study safety phase
24th Apr 202011:30 amRNSHolding(s) in Company
20th Apr 20207:00 amRNSPhase II study in COVID-19
17th Apr 20207:00 amRNSInterim analysis of Blautix phase II study data
17th Apr 20207:00 amRNSAppointment of Non-Executive Chairperson
30th Mar 202012:08 pmRNSSecond Price Monitoring Extn
30th Mar 202012:03 pmRNSPrice Monitoring Extension
19th Mar 20204:36 pmRNSPrice Monitoring Extension
19th Mar 20209:47 amRNSHolding(s) in Company
18th Mar 20204:44 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.